EZH2 underexpression
|
Rectal Cancer
|
EZH2 underexpression
|
Rectal Cancer
|
capecitabine Sensitive: C3 – Early Trials
|
capecitabine Sensitive: C3 – Early Trials
|
EZH2 underexpression
|
Soft Tissue Sarcoma
|
EZH2 underexpression
|
Soft Tissue Sarcoma
|
nivolumab + sunitinib Sensitive: C3 – Early Trials
|
nivolumab + sunitinib Sensitive: C3 – Early Trials
|